1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Market Access Impact: Non-Small Cell Lung Cancer (US) 2017

Market Access Impact: Non-Small Cell Lung Cancer (US) 2017

  • August 2017
  • ID: 4275614
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Eliminating market barriers could help lower-ranked brands a narrow lead

Three brands are way ahead in the US non-small cell lung cancer (NSCLC) market, thanks in part to market barriers that prevent oncologists from prescribing competing treatments. Eliminating these barriers won’t be enough for lower-ranked brands to catch up to the market leaders, but it could give a few of them the market share bump they need to overtake their closest rivals.

Get the details in Market Access Impact: NSCLC (US).

You’ll see how widely prescribed your brand is, and learn how 7 barriers affect your market share. You’ll also find out how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 100 US-based medical oncologists and primary care physicians, the report covers 13 major therapies from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck & Co., Novartis, Pfizer/Merck Group, and Roche


Top Takeaways

Barriers affect nearly 20% of prescriptions: High cost is the biggest issue, but each of the 6 other surveyed barriers affects roughly the same number of prescriptions.
Three brands dominate: Their respective market shares are at most 4% apart. However, significantly more doctors prescribe the top two brands than the third-place runner-up.
A battle of inches: Barriers only have a modest effect on market share, but it’s enough to hold at least two brands back. Eliminating barriers would push each of them up by one spot.
Problem areas: Some barriers have an outsized effect on some brands, e.g., high cost is the issue for one leading brand, while two lower-ranked rivals, have big reimbursement problems.
Barrier effect is widespread: At least 50% of doctors experience one or more barriers with every surveyed brand.
Overall perception is good: Most doctors either prescribe, or would consider prescribing all of the surveyed brands, and no more than 5% of doctors are unaware of any given brand.

Insight into 13 Major NSCLC Drugs

Avastin (bevacizumab; Roche)
Alecensa (alectinib; Roche)
Cyramza (ramucirumab; Eli Lilly)
Gilotrif (afatinib; Boehringer Ingelheim)
Iressa (gefitinib; AstraZeneca)
Keytruda (pembrolizumab; Merck & Co.)
Opdivo (nivolumab; Bristol-Myers Squibb)
Portrazza (necitumumab; Eli Lilly)
Tagrisso (osimertinib; AstraZeneca)
Tarceva (erlotinib; Roche)
Tecentriq (atezolizumab; Roche)
Xalkori (crizotinib; Pfizer/Merck Group)
Zykadia (ceritinib; Novartis)

Exploring Market Access Barriers

Market Access Impact: NSCLC (US) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

We surveyed 100 US-based medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with NSCLC in total in the last month

We conducted the survey between August 1st and 16th, 2017.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Immunology Partnering 2014-2019: Deal trends, players and financials

Global Immunology Partnering 2014-2019: Deal trends, players and financials

  • $ 2995
  • December 2019

Global Immunology Partnering 2014 to 2019 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.Trends in Immunology ...

Global Molecular Diagnostics Partnering Terms and Agreements 2014 to2019

Global Molecular Diagnostics Partnering Terms and Agreements 2014 to2019

  • $ 2995
  • December 2019

The Global Molecular Diagnostics Partnering 2014-2019 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals.These deals tend to be ...

Retrovirus Tests - Medical Devices Pipeline Assessment, 2019

Retrovirus Tests - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Retrovirus Tests - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Retrovirus Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Tests ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on